Bicara Therapeutics Inc. Deferred Tax Assets, Operating Loss Carryforwards, Domestic
Bicara Therapeutics Inc. (BCAX) had Deferred Tax Assets, Operating Loss Carryforwards, Domestic of $191.60 million as of 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic · last filed 2026-03-30
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $191.60M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $91.50M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $80.40M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Domestic |
|---|---|
| 2025-12-31 | $191.60M 10-K · filed 2026-03-30 |
| 2024-12-31 | $91.50M 10-K · filed 2026-03-30 |
| 2023-12-31 | $80.40M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |